ID   UBE3A_HUMAN             Reviewed;         875 AA.
AC   Q05086; A8K8Z9; P78355; Q93066; Q9UEP4; Q9UEP5; Q9UEP6; Q9UEP7;
AC   Q9UEP8; Q9UEP9;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   25-NOV-2008, sequence version 4.
DT   15-MAR-2017, entry version 177.
DE   RecName: Full=Ubiquitin-protein ligase E3A;
DE            EC=2.3.2.26;
DE   AltName: Full=E6AP ubiquitin-protein ligase;
DE   AltName: Full=HECT-type ubiquitin transferase E3A;
DE   AltName: Full=Human papillomavirus E6-associated protein;
DE   AltName: Full=Oncogenic protein-associated protein E6-AP;
DE   AltName: Full=Renal carcinoma antigen NY-REN-54;
GN   Name=UBE3A; Synonyms=E6AP, EPVE6AP, HPVE6A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS I; II AND III), AND
RP   VARIANT GLY-290.
RC   TISSUE=Keratinocyte;
RX   PubMed=9143503; DOI=10.1006/geno.1997.4617;
RA   Yamamoto Y., Huibregtse J.M., Howley P.M.;
RT   "The human E6-AP gene (UBE3A) encodes three potential protein isoforms
RT   generated by differential splicing.";
RL   Genomics 41:263-266(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM I).
RC   TISSUE=Fetal brain;
RX   PubMed=8988171; DOI=10.1038/ng0197-70;
RA   Kishino T., Lalande M., Wagstaff J.;
RT   "UBE3A/E6-AP mutations cause Angelman syndrome.";
RL   Nat. Genet. 15:70-73(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM I), AND VARIANTS TYR-44 AND
RP   THR-201.
RX   PubMed=8988172; DOI=10.1038/ng0197-74;
RA   Matsuura T., Sutcliffe J.S., Fang P., Galjaard R.-J., Jiang Y.-H.,
RA   Benton C.S., Rommens J.M., Beaudet A.L.;
RT   "De novo truncating mutations in E6-AP ubiquitin-protein ligase gene
RT   (UBE3A) in Angelman syndrome.";
RL   Nat. Genet. 15:74-77(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM III).
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R.,
RA   Fahey J., Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G.,
RA   Johnson E., Jones C., Kamat A., Kaur A., Locke D.P., Madan A.,
RA   Munson G., Jaffe D.B., Lui A., Macdonald P., Mauceli E., Naylor J.W.,
RA   Nesbitt R., Nicol R., O'Leary S.B., Ratcliffe A., Rounsley S., She X.,
RA   Sneddon K.M.B., Stewart S., Sougnez C., Stone S.M., Topham K.,
RA   Vincent D., Wang S., Zimmer A.R., Birren B.W., Hood L., Lander E.S.,
RA   Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human
RT   chromosome 15.";
RL   Nature 440:671-675(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 11-875, PARTIAL PROTEIN SEQUENCE,
RP   CHARACTERIZATION, AND VARIANT GLY-290.
RC   TISSUE=Keratinocyte;
RX   PubMed=8380895; DOI=10.1128/MCB.13.2.775;
RA   Huibregtse J.M., Scheffner M., Howley P.M.;
RT   "Cloning and expression of the cDNA for E6-AP, a protein that mediates
RT   the interaction of the human papillomavirus E6 oncoprotein with p53.";
RL   Mol. Cell. Biol. 13:775-784(1993).
RN   [8]
RP   CHARACTERIZATION.
RX   PubMed=9688277; DOI=10.1046/j.1432-1327.1998.2540643.x;
RA   Nuber U., Schwarz S.E., Scheffner M.;
RT   "The ubiquitin-protein ligase E6-associated protein (E6-AP) serves as
RT   its own substrate.";
RL   Eur. J. Biochem. 254:643-649(1998).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 25-787, AND VARIANT GLY-290.
RA   Hennies H.C., Buerger J., Sperling K., Reis A.;
RT   "Mutations in the E6-AP gene (UBE3A) in patients with Angelman
RT   syndrome.";
RL   Submitted (AUG-1997) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   IDENTIFICATION AS A RENAL CANCER ANTIGEN.
RC   TISSUE=Renal cell carcinoma;
RX   PubMed=10508479;
RX   DOI=10.1002/(SICI)1097-0215(19991112)83:4<456::AID-IJC4>3.0.CO;2-5;
RA   Scanlan M.J., Gordan J.D., Williamson B., Stockert E., Bander N.H.,
RA   Jongeneel C.V., Gure A.O., Jaeger D., Jaeger E., Knuth A., Chen Y.-T.,
RA   Old L.J.;
RT   "Antigens recognized by autologous antibody in patients with renal-
RT   cell carcinoma.";
RL   Int. J. Cancer 83:456-464(1999).
RN   [11]
RP   FUNCTION.
RX   PubMed=10373495; DOI=10.1074/jbc.274.26.18785;
RA   Kumar S., Talis A.L., Howley P.M.;
RT   "Identification of HHR23A as a substrate for E6-associated protein-
RT   mediated ubiquitination.";
RL   J. Biol. Chem. 274:18785-18792(1999).
RN   [12]
RP   INTERACTION WITH UBQLN1 AND UBQLN2.
RX   PubMed=10983987; DOI=10.1016/S1097-2765(00)00040-X;
RA   Kleijnen M.F., Shih A.H., Zhou P., Kumar S., Soccio R.E.,
RA   Kedersha N.L., Gill G., Howley P.M.;
RT   "The hPLIC proteins may provide a link between the ubiquitination
RT   machinery and the proteasome.";
RL   Mol. Cell 6:409-419(2000).
RN   [13]
RP   INTERACTION WITH BPY2.
RX   PubMed=12207887; DOI=10.1016/S0006-291X(02)02040-5;
RA   Wong E.Y., Tse J.Y., Yao K.M., Tam P.C., Yeung W.S.;
RT   "VCY2 protein interacts with the HECT domain of ubiquitin-protein
RT   ligase E3A.";
RL   Biochem. Biophys. Res. Commun. 296:1104-1111(2002).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17323924; DOI=10.1021/bi061994u;
RA   Wang X., Chen C.-F., Baker P.R., Chen P.-L., Kaiser P., Huang L.;
RT   "Mass spectrometric characterization of the affinity-purified human
RT   26S proteasome complex.";
RL   Biochemistry 46:3553-3565(2007).
RN   [15]
RP   INTERACTION WITH HCV CORE PROTEIN.
RX   PubMed=17108031; DOI=10.1128/JVI.01684-06;
RA   Shirakura M., Murakami K., Ichimura T., Suzuki R., Shimoji T.,
RA   Fukuda K., Abe K., Sato S., Fukasawa M., Yamakawa Y., Nishijima M.,
RA   Moriishi K., Matsuura Y., Wakita T., Suzuki T., Howley P.M.,
RA   Miyamura T., Shoji I.;
RT   "E6AP ubiquitin ligase mediates ubiquitylation and degradation of
RT   hepatitis C virus core protein.";
RL   J. Virol. 81:1174-1185(2007).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-218, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [17]
RP   FUNCTION.
RX   PubMed=19325566; DOI=10.1038/cdd.2009.31;
RA   Louria-Hayon I., Alsheich-Bartok O., Levav-Cohen Y., Silberman I.,
RA   Berger M., Grossman T., Matentzoglu K., Jiang Y.H., Muller S.,
RA   Scheffner M., Haupt S., Haupt Y.;
RT   "E6AP promotes the degradation of the PML tumor suppressor.";
RL   Cell Death Differ. 16:1156-1166(2009).
RN   [18]
RP   FUNCTION.
RX   PubMed=19233847; DOI=10.1074/jbc.M806804200;
RA   Mishra A., Godavarthi S.K., Maheshwari M., Goswami A., Jana N.R.;
RT   "The ubiquitin ligase E6-AP is induced and recruited to aggresomes in
RT   response to proteasome inhibition and may be involved in the
RT   ubiquitination of Hsp70-bound misfolded proteins.";
RL   J. Biol. Chem. 284:10537-10545(2009).
RN   [19]
RP   FUNCTION.
RX   PubMed=19204938; DOI=10.1002/jcb.22096;
RA   Shimoji T., Murakami K., Sugiyama Y., Matsuda M., Inubushi S.,
RA   Nasu J., Shirakura M., Suzuki T., Wakita T., Kishino T., Hotta H.,
RA   Miyamura T., Shoji I.;
RT   "Identification of annexin A1 as a novel substrate for E6AP-mediated
RT   ubiquitylation.";
RL   J. Cell. Biochem. 106:1123-1135(2009).
RN   [20]
RP   FUNCTION.
RX   PubMed=19591933; DOI=10.1016/j.nbd.2009.06.010;
RA   Mishra A., Godavarthi S.K., Jana N.R.;
RT   "UBE3A/E6-AP regulates cell proliferation by promoting proteasomal
RT   degrADation of p27.";
RL   Neurobiol. Dis. 36:26-34(2009).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-218, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [23]
RP   FUNCTION, AND INTERACTION WITH HIF1AN; MAPK6; NEURL4 AND PSMD4.
RX   PubMed=22645313; DOI=10.1128/MCB.00201-12;
RA   Martinez-Noel G., Galligan J.T., Sowa M.E., Arndt V., Overton T.M.,
RA   Harper J.W., Howley P.M.;
RT   "Identification and proteomic analysis of distinct UBE3A/E6AP protein
RT   complexes.";
RL   Mol. Cell. Biol. 32:3095-3106(2012).
RN   [24]
RP   PHOSPHORYLATION AT TYR-659.
RX   PubMed=23581475; DOI=10.1021/bi301710c;
RA   Chan A.L., Grossman T., Zuckerman V., Campigli Di Giammartino D.,
RA   Moshel O., Scheffner M., Monahan B., Pilling P., Jiang Y.H., Haupt S.,
RA   Schueler-Furman O., Haupt Y.;
RT   "c-Abl phosphorylates E6AP and regulates its E3 ubiquitin ligase
RT   activity.";
RL   Biochemistry 52:3119-3129(2013).
RN   [25]
RP   SUBUNIT, AND MUTAGENESIS OF PHE-750.
RX   PubMed=24273172; DOI=10.1074/jbc.M113.517805;
RA   Ronchi V.P., Klein J.M., Edwards D.J., Haas A.L.;
RT   "The active form of E6-associated protein (E6AP)/UBE3A ubiquitin
RT   ligase is an oligomer.";
RL   J. Biol. Chem. 289:1033-1048(2014).
RN   [26]
RP   FUNCTION, AND INTERACTION WITH ARNTL.
RX   PubMed=24728990; DOI=10.1093/nar/gku225;
RA   Gossan N.C., Zhang F., Guo B., Jin D., Yoshitane H., Yao A.,
RA   Glossop N., Zhang Y.Q., Fukada Y., Meng Q.J.;
RT   "The E3 ubiquitin ligase UBE3A is an integral component of the
RT   molecular circadian clock through regulating the BMAL1 transcription
RT   factor.";
RL   Nucleic Acids Res. 42:5765-5775(2014).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 495-852 IN COMPLEX WITH
RP   UBE2L3.
RX   PubMed=10558980; DOI=10.1126/science.286.5443.1321;
RA   Huang L., Kinnucan E., Wang G., Beaudenon S., Howley P.M.,
RA   Huibregtse J.M., Pavletich N.P.;
RT   "Structure of an E6AP-UbcH7 complex: insights into ubiquitination by
RT   the E2-E3 enzyme cascade.";
RL   Science 286:1321-1326(1999).
RN   [28]
RP   STRUCTURE BY NMR OF 401-418.
RX   PubMed=11170455; DOI=10.1021/bi0019592;
RA   Be X., Hong Y., Wei J., Androphy E.J., Chen J.J., Baleja J.D.;
RT   "Solution structure determination and mutational analysis of the
RT   papillomavirus E6 interacting peptide of E6AP.";
RL   Biochemistry 40:1293-1299(2001).
RN   [29]
RP   STRUCTURE BY NMR OF 24-87, AND ZINC-FINGER.
RX   PubMed=21947926; DOI=10.1007/s10858-011-9552-y;
RA   Lemak A., Yee A., Bezsonova I., Dhe-Paganon S., Arrowsmith C.H.;
RT   "Zn-binding AZUL domain of human ubiquitin protein ligase Ube3A.";
RL   J. Biomol. NMR 51:185-190(2011).
RN   [30]
RP   VARIANT AS ILE-826 INS, VARIANTS HIS-62; THR-201 AND PRO-372, AND
RP   INVOLVEMENT IN AS.
RX   PubMed=9585605; DOI=10.1086/301877;
RA   Malzac P., Webber H., Moncla A., Graham J.M. Jr., Kukolich M.,
RA   Williams C., Pagon R.A., Ramsdell L.A., Kishino T., Wagstaff J.;
RT   "Mutation analysis of UBE3A in Angelman syndrome patients.";
RL   Am. J. Hum. Genet. 62:1353-1360(1998).
RN   [31]
RP   VARIANTS AS LYS-129; VAL-235; GLN-260; HIS-260; TRP-286; PRO-458;
RP   LEU-481; PRO-500; ARG-568; LYS-589; GLN-607; ILE-679; CYS-713 AND
RP   LEU-850, AND VARIANTS ARG-140; GLY-156; THR-293; THR-358; ILE-501;
RP   GLU-611; PRO-611; ARG-696 AND ILE-785.
RX   PubMed=25212744; DOI=10.1002/humu.22687;
RA   Sadikovic B., Fernandes P., Zhang V.W., Ward P.A., Miloslavskaya I.,
RA   Rhead W., Rosenbaum R., Gin R., Roa B., Fang P.;
RT   "Mutation update for UBE3A variants in Angelman syndrome.";
RL   Hum. Mutat. 35:1407-1417(2014).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase which accepts ubiquitin from
CC       an E2 ubiquitin-conjugating enzyme in the form of a thioester and
CC       transfers it to its substrates. Several substrates have been
CC       identified including the RAD23A and RAD23B, MCM7 (which is
CC       involved in DNA replication), annexin A1, the PML tumor
CC       suppressor, and the cell cycle regulator CDKN1B. Catalyzes the
CC       high-risk human papilloma virus E6-mediated ubiquitination of
CC       p53/TP53, contributing to the neoplastic progression of cells
CC       infected by these viruses. Additionally, may function as a
CC       cellular quality control ubiquitin ligase by helping the
CC       degradation of the cytoplasmic misfolded proteins. Finally, UBE3A
CC       also promotes its own degradation in vivo. Plays an important role
CC       in the regulation of the circadian clock: involved in the
CC       ubiquitination of the core clock component ARNTL/BMAL1, leading to
CC       its proteasomal degradation (PubMed:24728990).
CC       {ECO:0000269|PubMed:10373495, ECO:0000269|PubMed:19204938,
CC       ECO:0000269|PubMed:19233847, ECO:0000269|PubMed:19325566,
CC       ECO:0000269|PubMed:19591933, ECO:0000269|PubMed:22645313,
CC       ECO:0000269|PubMed:24728990}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: The active form is probably a homotrimer. Binds UBQLN1
CC       and UBQLN2. Interacts with the 26S proteasome. Interacts with HCV
CC       core protein and targets it to degradation. Interacts with the E6
CC       protein of the cancer-associated human papillomavirus types 16 and
CC       18. The E6/E6-AP complex binds to and targets the p53/TP53 tumor-
CC       suppressor protein for ubiquitin-mediated proteolysis. Interacts
CC       with BPY2. Interacts with HIF1AN, MAPK6 AND NEURL4; interaction
CC       with MAPK6 may be mediated by NEURL4. Interacts with the
CC       proteasomal subunit PSMD4. Interacts with ARNTL/BMAL1.
CC       {ECO:0000269|PubMed:10558980, ECO:0000269|PubMed:10983987,
CC       ECO:0000269|PubMed:12207887, ECO:0000269|PubMed:17108031,
CC       ECO:0000269|PubMed:22645313, ECO:0000269|PubMed:24273172,
CC       ECO:0000269|PubMed:24728990}.
CC   -!- INTERACTION:
CC       B3KPL7:-; NbExp=3; IntAct=EBI-10175863, EBI-10175860;
CC       Q9NZD4:AHSP; NbExp=3; IntAct=EBI-10175863, EBI-720250;
CC       Q8TDY4:ASAP3; NbExp=3; IntAct=EBI-10175863, EBI-2609717;
CC       Q7Z3C6:ATG9A; NbExp=3; IntAct=EBI-10175863, EBI-727146;
CC       P03126:E6 (xeno); NbExp=3; IntAct=EBI-954357, EBI-1177242;
CC       P04019:E6 (xeno); NbExp=5; IntAct=EBI-954357, EBI-1177232;
CC       P06462:E6 (xeno); NbExp=2; IntAct=EBI-954357, EBI-7069993;
CC       P06463:E6 (xeno); NbExp=6; IntAct=EBI-954357, EBI-1186926;
CC       P06931:E6 (xeno); NbExp=2; IntAct=EBI-954357, EBI-7281937;
CC       Q77E16:E6 (xeno); NbExp=3; IntAct=EBI-954357, EBI-7011359;
CC       Q2WGJ6:KLHL38; NbExp=3; IntAct=EBI-10175863, EBI-6426443;
CC       A1L4G7:TAT; NbExp=3; IntAct=EBI-10175863, EBI-10223561;
CC       P17735:TAT; NbExp=8; IntAct=EBI-11026619, EBI-12046643;
CC       P04637:TP53; NbExp=3; IntAct=EBI-954357, EBI-366083;
CC       Q5U5U6:UBB; NbExp=3; IntAct=EBI-10175863, EBI-1642104;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250|UniProtKB:O08759}.
CC       Cytoplasm {ECO:0000250|UniProtKB:O08759}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=II;
CC         IsoId=Q05086-1; Sequence=Displayed;
CC       Name=I;
CC         IsoId=Q05086-2; Sequence=VSP_006705;
CC       Name=III;
CC         IsoId=Q05086-3; Sequence=VSP_006706;
CC   -!- PTM: Phosphorylation at Tyr-659 by ABL1 impairs E3 ligase activity
CC       and protects p53/TP53 from degradation in (HPV)-infected cells.
CC       {ECO:0000269|PubMed:23581475}.
CC   -!- DISEASE: Angelman syndrome (AS) [MIM:105830]: A neurodevelopmental
CC       disorder characterized by severe motor and intellectual
CC       retardation, ataxia, frequent jerky limb movements and flapping of
CC       the arms and hands, hypotonia, seizures, absence of speech,
CC       frequent smiling and episodes of paroxysmal laughter, open-mouthed
CC       expression revealing the tongue. {ECO:0000269|PubMed:25212744,
CC       ECO:0000269|PubMed:9585605}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: A cysteine residue is required for ubiquitin-
CC       thioester formation.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/UBE3AID42756ch15q11.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X98021; CAA66653.1; -; Genomic_DNA.
DR   EMBL; X98027; CAA66653.1; JOINED; Genomic_DNA.
DR   EMBL; X98022; CAA66653.1; JOINED; Genomic_DNA.
DR   EMBL; X98023; CAA66653.1; JOINED; Genomic_DNA.
DR   EMBL; X98024; CAA66653.1; JOINED; Genomic_DNA.
DR   EMBL; X98025; CAA66653.1; JOINED; Genomic_DNA.
DR   EMBL; X98026; CAA66653.1; JOINED; Genomic_DNA.
DR   EMBL; X98028; CAA66653.1; JOINED; Genomic_DNA.
DR   EMBL; X98029; CAA66653.1; JOINED; Genomic_DNA.
DR   EMBL; X98030; CAA66653.1; JOINED; Genomic_DNA.
DR   EMBL; X98031; CAA66654.1; -; mRNA.
DR   EMBL; X98032; CAA66655.1; -; mRNA.
DR   EMBL; X98033; CAA66656.1; -; mRNA.
DR   EMBL; AC100774; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AK292514; BAF85203.1; -; mRNA.
DR   EMBL; AC124997; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471151; EAW57645.1; -; Genomic_DNA.
DR   EMBL; L07557; AAA35542.1; -; mRNA.
DR   EMBL; AF016708; AAB69154.1; -; Genomic_DNA.
DR   EMBL; AF016703; AAB69154.1; JOINED; Genomic_DNA.
DR   EMBL; AF016704; AAB69154.1; JOINED; Genomic_DNA.
DR   EMBL; AF016705; AAB69154.1; JOINED; Genomic_DNA.
DR   EMBL; AF016706; AAB69154.1; JOINED; Genomic_DNA.
DR   EMBL; AF016707; AAB69154.1; JOINED; Genomic_DNA.
DR   EMBL; U84404; AAB49301.1; -; mRNA.
DR   EMBL; AJ001107; CAA04534.1; -; Genomic_DNA.
DR   EMBL; AJ001108; CAA04535.1; -; Genomic_DNA.
DR   EMBL; AJ001109; CAA04536.1; -; Genomic_DNA.
DR   EMBL; AJ001110; CAA04537.1; -; Genomic_DNA.
DR   EMBL; AJ001111; CAA04538.1; -; Genomic_DNA.
DR   EMBL; AJ001112; CAA04539.1; -; Genomic_DNA.
DR   CCDS; CCDS32177.1; -. [Q05086-2]
DR   CCDS; CCDS45191.1; -. [Q05086-3]
DR   CCDS; CCDS45192.1; -. [Q05086-1]
DR   RefSeq; NP_000453.2; NM_000462.3. [Q05086-1]
DR   RefSeq; NP_570853.1; NM_130838.1. [Q05086-2]
DR   RefSeq; NP_570854.1; NM_130839.2. [Q05086-3]
DR   RefSeq; XP_005268324.1; XM_005268267.4. [Q05086-2]
DR   RefSeq; XP_005268325.1; XM_005268268.4. [Q05086-2]
DR   RefSeq; XP_005268326.1; XM_005268269.4. [Q05086-2]
DR   RefSeq; XP_005268327.1; XM_005268270.4. [Q05086-2]
DR   RefSeq; XP_005268328.1; XM_005268271.4. [Q05086-2]
DR   RefSeq; XP_006720738.1; XM_006720675.3. [Q05086-2]
DR   RefSeq; XP_006720739.1; XM_006720676.3. [Q05086-2]
DR   RefSeq; XP_011520296.1; XM_011521994.2. [Q05086-1]
DR   RefSeq; XP_011520297.1; XM_011521995.2. [Q05086-1]
DR   RefSeq; XP_016878033.1; XM_017022544.1. [Q05086-1]
DR   RefSeq; XP_016878034.1; XM_017022545.1. [Q05086-1]
DR   RefSeq; XP_016878035.1; XM_017022546.1. [Q05086-1]
DR   RefSeq; XP_016878036.1; XM_017022547.1. [Q05086-3]
DR   RefSeq; XP_016878037.1; XM_017022548.1. [Q05086-3]
DR   RefSeq; XP_016878038.1; XM_017022549.1. [Q05086-3]
DR   RefSeq; XP_016878039.1; XM_017022550.1. [Q05086-3]
DR   RefSeq; XP_016878040.1; XM_017022551.1. [Q05086-2]
DR   RefSeq; XP_016878041.1; XM_017022552.1. [Q05086-2]
DR   RefSeq; XP_016878042.1; XM_017022553.1. [Q05086-2]
DR   RefSeq; XP_016878043.1; XM_017022554.1. [Q05086-2]
DR   RefSeq; XP_016878044.1; XM_017022555.1. [Q05086-2]
DR   UniGene; Hs.598862; -.
DR   PDB; 1C4Z; X-ray; 2.60 A; A/B/C=518-875.
DR   PDB; 1D5F; X-ray; 2.80 A; A/B/C=518-875.
DR   PDB; 1EQX; NMR; -; A=401-418.
DR   PDB; 2KR1; NMR; -; A=24-87.
DR   PDB; 4GIZ; X-ray; 2.55 A; A/B=403-414.
DR   PDBsum; 1C4Z; -.
DR   PDBsum; 1D5F; -.
DR   PDBsum; 1EQX; -.
DR   PDBsum; 2KR1; -.
DR   PDBsum; 4GIZ; -.
DR   ProteinModelPortal; Q05086; -.
DR   SMR; Q05086; -.
DR   BioGrid; 113185; 174.
DR   DIP; DIP-6002N; -.
DR   IntAct; Q05086; 59.
DR   MINT; MINT-147444; -.
DR   STRING; 9606.ENSP00000381045; -.
DR   iPTMnet; Q05086; -.
DR   PhosphoSitePlus; Q05086; -.
DR   BioMuta; UBE3A; -.
DR   DMDM; 215274240; -.
DR   EPD; Q05086; -.
DR   MaxQB; Q05086; -.
DR   PaxDb; Q05086; -.
DR   PeptideAtlas; Q05086; -.
DR   PRIDE; Q05086; -.
DR   DNASU; 7337; -.
DR   Ensembl; ENST00000232165; ENSP00000232165; ENSG00000114062. [Q05086-2]
DR   Ensembl; ENST00000397954; ENSP00000381045; ENSG00000114062. [Q05086-1]
DR   Ensembl; ENST00000428984; ENSP00000401265; ENSG00000114062. [Q05086-2]
DR   Ensembl; ENST00000438097; ENSP00000411258; ENSG00000114062. [Q05086-2]
DR   Ensembl; ENST00000566215; ENSP00000457771; ENSG00000114062. [Q05086-2]
DR   Ensembl; ENST00000614096; ENSP00000481796; ENSG00000114062. [Q05086-3]
DR   Ensembl; ENST00000630424; ENSP00000486349; ENSG00000114062. [Q05086-2]
DR   Ensembl; ENST00000637886; ENSP00000490258; ENSG00000114062. [Q05086-3]
DR   Ensembl; ENST00000638011; ENSP00000490111; ENSG00000114062. [Q05086-2]
DR   Ensembl; ENST00000638155; ENSP00000490557; ENSG00000114062. [Q05086-2]
DR   GeneID; 7337; -.
DR   KEGG; hsa:7337; -.
DR   UCSC; uc001zaq.4; human. [Q05086-1]
DR   CTD; 7337; -.
DR   DisGeNET; 7337; -.
DR   GeneCards; UBE3A; -.
DR   GeneReviews; UBE3A; -.
DR   HGNC; HGNC:12496; UBE3A.
DR   HPA; CAB009723; -.
DR   HPA; HPA039410; -.
DR   HPA; HPA040380; -.
DR   MalaCards; UBE3A; -.
DR   MIM; 105830; phenotype.
DR   MIM; 601623; gene.
DR   neXtProt; NX_Q05086; -.
DR   OpenTargets; ENSG00000114062; -.
DR   Orphanet; 72; Angelman syndrome.
DR   PharmGKB; PA37144; -.
DR   eggNOG; KOG0941; Eukaryota.
DR   eggNOG; COG5021; LUCA.
DR   GeneTree; ENSGT00870000136406; -.
DR   HOVERGEN; HBG059326; -.
DR   InParanoid; Q05086; -.
DR   KO; K10587; -.
DR   OMA; NAFRKGF; -.
DR   OrthoDB; EOG091G01LV; -.
DR   PhylomeDB; Q05086; -.
DR   TreeFam; TF315189; -.
DR   BRENDA; 2.3.2.B9; 2681.
DR   BRENDA; 6.3.2.19; 2681.
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   SIGNOR; Q05086; -.
DR   UniPathway; UPA00143; -.
DR   EvolutionaryTrace; Q05086; -.
DR   GeneWiki; UBE3A; -.
DR   GenomeRNAi; 7337; -.
DR   PRO; PR:Q05086; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   Bgee; ENSG00000114062; -.
DR   ExpressionAtlas; Q05086; baseline and differential.
DR   Genevisible; Q05086; HS.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0000502; C:proteasome complex; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0003713; F:transcription coactivator activity; IEA:Ensembl.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IMP:CACAO.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB.
DR   GO; GO:0030521; P:androgen receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0007420; P:brain development; TAS:ProtInc.
DR   GO; GO:0001541; P:ovarian follicle development; IEA:Ensembl.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IEA:Ensembl.
DR   GO; GO:0031398; P:positive regulation of protein ubiquitination; IDA:CACAO.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0060736; P:prostate gland growth; IEA:Ensembl.
DR   GO; GO:0051865; P:protein autoubiquitination; IDA:FlyBase.
DR   GO; GO:0070936; P:protein K48-linked ubiquitination; IDA:UniProtKB.
DR   GO; GO:0006508; P:proteolysis; TAS:ProtInc.
DR   GO; GO:0042752; P:regulation of circadian rhythm; IMP:UniProtKB.
DR   GO; GO:2000058; P:regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process; IMP:UniProtKB.
DR   GO; GO:0035037; P:sperm entry; IEA:Ensembl.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; TAS:ProtInc.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   CDD; cd00078; HECTc; 1.
DR   InterPro; IPR032353; AZUL.
DR   InterPro; IPR000569; HECT_dom.
DR   InterPro; IPR017134; UBE3A.
DR   Pfam; PF16558; AZUL; 1.
DR   Pfam; PF00632; HECT; 1.
DR   PIRSF; PIRSF037201; Ubiquitin-protein_ligase_E6-AP; 1.
DR   SMART; SM00119; HECTc; 1.
DR   SUPFAM; SSF56204; SSF56204; 1.
DR   PROSITE; PS50237; HECT; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Biological rhythms;
KW   Complete proteome; Cytoplasm; Direct protein sequencing;
KW   Disease mutation; Host-virus interaction; Metal-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Proteasome; Reference proteome;
KW   Transferase; Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN         1    875       Ubiquitin-protein ligase E3A.
FT                                /FTId=PRO_0000194980.
FT   DOMAIN      776    875       HECT. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00104}.
FT   ZN_FING      44     83       C4-type; atypical.
FT                                {ECO:0000269|PubMed:21947926}.
FT   REGION      401    418       E6-binding.
FT   REGION      418    517       Interaction with HCV core protein.
FT   COMPBIAS    394    399       Asp/Glu-rich (acidic).
FT   ACT_SITE    843    843       Glycyl thioester intermediate.
FT   MOD_RES     218    218       Phosphoserine.
FT                                {ECO:0000244|PubMed:17525332,
FT                                ECO:0000244|PubMed:19690332}.
FT   MOD_RES     659    659       Phosphotyrosine; by ABL1.
FT                                {ECO:0000269|PubMed:23581475}.
FT   VAR_SEQ       1     23       Missing (in isoform I).
FT                                {ECO:0000303|PubMed:8988171,
FT                                ECO:0000303|PubMed:9143503}.
FT                                /FTId=VSP_006705.
FT   VAR_SEQ       1     10       MEKLHQCYWK -> MATACKR (in isoform III).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:9143503}.
FT                                /FTId=VSP_006706.
FT   VARIANT      44     44       C -> Y (probable polymorphism).
FT                                {ECO:0000269|PubMed:8988172}.
FT                                /FTId=VAR_007852.
FT   VARIANT      62     62       R -> H (in dbSNP:rs587784511).
FT                                {ECO:0000269|PubMed:9585605}.
FT                                /FTId=VAR_008142.
FT   VARIANT     129    129       T -> K (in AS; unknown pathological
FT                                significance; dbSNP:rs587781241).
FT                                {ECO:0000269|PubMed:25212744}.
FT                                /FTId=VAR_073196.
FT   VARIANT     140    140       C -> R (common polymorphism; may be
FT                                associated with AS; dbSNP:rs587782907).
FT                                {ECO:0000269|PubMed:25212744}.
FT                                /FTId=VAR_073197.
FT   VARIANT     156    156       V -> G (common polymorphism; may be
FT                                associated with AS; dbSNP:rs587782915).
FT                                {ECO:0000269|PubMed:25212744}.
FT                                /FTId=VAR_073198.
FT   VARIANT     201    201       A -> T (in dbSNP:rs147145506).
FT                                {ECO:0000269|PubMed:8988172,
FT                                ECO:0000269|PubMed:9585605}.
FT                                /FTId=VAR_007853.
FT   VARIANT     235    235       D -> V (in AS; unknown pathological
FT                                significance; dbSNP:rs587780581).
FT                                {ECO:0000269|PubMed:25212744}.
FT                                /FTId=VAR_073199.
FT   VARIANT     260    260       L -> H (in AS; unknown pathological
FT                                significance; dbSNP:rs587780582).
FT                                {ECO:0000269|PubMed:25212744}.
FT                                /FTId=VAR_073200.
FT   VARIANT     260    260       L -> Q (in AS; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:25212744}.
FT                                /FTId=VAR_073201.
FT   VARIANT     286    286       L -> W (in AS; unknown pathological
FT                                significance; dbSNP:rs587780583).
FT                                {ECO:0000269|PubMed:25212744}.
FT                                /FTId=VAR_073202.
FT   VARIANT     290    290       V -> G (in dbSNP:rs1059383).
FT                                {ECO:0000269|PubMed:8380895,
FT                                ECO:0000269|PubMed:9143503,
FT                                ECO:0000269|Ref.9}.
FT                                /FTId=VAR_047516.
FT   VARIANT     293    293       N -> T (common polymorphism; may be
FT                                associated with AS; dbSNP:rs587782908).
FT                                {ECO:0000269|PubMed:25212744}.
FT                                /FTId=VAR_073203.
FT   VARIANT     358    358       S -> T (common polymorphism; may be
FT                                associated with AS; dbSNP:rs141984760).
FT                                {ECO:0000269|PubMed:25212744}.
FT                                /FTId=VAR_073204.
FT   VARIANT     372    372       S -> P. {ECO:0000269|PubMed:9585605}.
FT                                /FTId=VAR_008143.
FT   VARIANT     458    458       L -> P (in AS; unknown pathological
FT                                significance; dbSNP:rs587781242).
FT                                {ECO:0000269|PubMed:25212744}.
FT                                /FTId=VAR_073205.
FT   VARIANT     481    481       P -> L (in AS; unknown pathological
FT                                significance; dbSNP:rs587780584).
FT                                {ECO:0000269|PubMed:25212744}.
FT                                /FTId=VAR_073206.
FT   VARIANT     500    500       R -> P (in AS; unknown pathological
FT                                significance; dbSNP:rs587781243).
FT                                {ECO:0000269|PubMed:25212744}.
FT                                /FTId=VAR_073207.
FT   VARIANT     501    501       M -> I (common polymorphism; may be
FT                                associated with AS; dbSNP:rs587782916).
FT                                {ECO:0000269|PubMed:25212744}.
FT                                /FTId=VAR_073208.
FT   VARIANT     568    568       G -> R (in AS; unknown pathological
FT                                significance; dbSNP:rs587781233).
FT                                {ECO:0000269|PubMed:25212744}.
FT                                /FTId=VAR_073209.
FT   VARIANT     589    589       M -> K (in AS; unknown pathological
FT                                significance; dbSNP:rs587781244).
FT                                {ECO:0000269|PubMed:25212744}.
FT                                /FTId=VAR_073210.
FT   VARIANT     607    607       E -> Q (in AS; unknown pathological
FT                                significance; dbSNP:rs587781235).
FT                                {ECO:0000269|PubMed:25212744}.
FT                                /FTId=VAR_073211.
FT   VARIANT     611    611       Q -> E (common polymorphism; may be
FT                                associated with AS; dbSNP:rs587782918).
FT                                {ECO:0000269|PubMed:25212744}.
FT                                /FTId=VAR_073212.
FT   VARIANT     611    611       Q -> P (common polymorphism; may be
FT                                associated with AS; dbSNP:rs587782919).
FT                                {ECO:0000269|PubMed:25212744}.
FT                                /FTId=VAR_073213.
FT   VARIANT     679    679       T -> I (in AS; unknown pathological
FT                                significance; dbSNP:rs587781236).
FT                                {ECO:0000269|PubMed:25212744}.
FT                                /FTId=VAR_073214.
FT   VARIANT     696    696       L -> R (common polymorphism; may be
FT                                associated with AS; dbSNP:rs587782920).
FT                                {ECO:0000269|PubMed:25212744}.
FT                                /FTId=VAR_073215.
FT   VARIANT     713    713       F -> C (in AS; unknown pathological
FT                                significance; dbSNP:rs587781237).
FT                                {ECO:0000269|PubMed:25212744}.
FT                                /FTId=VAR_073216.
FT   VARIANT     785    785       V -> I (common polymorphism; may be
FT                                associated with AS; dbSNP:rs587782910).
FT                                {ECO:0000269|PubMed:25212744}.
FT                                /FTId=VAR_073217.
FT   VARIANT     826    826       I -> II (in AS).
FT                                {ECO:0000269|PubMed:9585605}.
FT                                /FTId=VAR_008144.
FT   VARIANT     850    850       P -> L (in AS; unknown pathological
FT                                significance; dbSNP:rs587781239).
FT                                {ECO:0000269|PubMed:25212744}.
FT                                /FTId=VAR_073218.
FT   MUTAGEN     750    750       F->D: Disrupt trimer formation, 50-fold
FT                                reduction in E3 ligase activity.
FT                                {ECO:0000269|PubMed:24273172}.
FT   CONFLICT    359    359       R -> RNLVNEFNSR (in Ref. 7; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    423    423       P -> L (in Ref. 7; AAA35542).
FT                                {ECO:0000305}.
FT   CONFLICT    647    649       TFR -> LFV (in Ref. 7; AAA35542).
FT                                {ECO:0000305}.
FT   CONFLICT    669    669       E -> V (in Ref. 7; AAA35542).
FT                                {ECO:0000305}.
FT   CONFLICT    686    686       D -> N (in Ref. 7; AAA35542).
FT                                {ECO:0000305}.
FT   HELIX        27     41       {ECO:0000244|PDB:2KR1}.
FT   HELIX        65     78       {ECO:0000244|PDB:2KR1}.
FT   HELIX       403    410       {ECO:0000244|PDB:4GIZ}.
FT   STRAND      525    527       {ECO:0000244|PDB:1C4Z}.
FT   STRAND      529    531       {ECO:0000244|PDB:1C4Z}.
FT   HELIX       532    545       {ECO:0000244|PDB:1C4Z}.
FT   HELIX       548    552       {ECO:0000244|PDB:1C4Z}.
FT   STRAND      557    559       {ECO:0000244|PDB:1C4Z}.
FT   HELIX       569    582       {ECO:0000244|PDB:1C4Z}.
FT   HELIX       585    587       {ECO:0000244|PDB:1C4Z}.
FT   STRAND      589    592       {ECO:0000244|PDB:1C4Z}.
FT   TURN        594    596       {ECO:0000244|PDB:1C4Z}.
FT   STRAND      599    601       {ECO:0000244|PDB:1C4Z}.
FT   HELIX       609    624       {ECO:0000244|PDB:1C4Z}.
FT   HELIX       635    641       {ECO:0000244|PDB:1C4Z}.
FT   HELIX       648    654       {ECO:0000244|PDB:1C4Z}.
FT   HELIX       656    667       {ECO:0000244|PDB:1C4Z}.
FT   HELIX       672    675       {ECO:0000244|PDB:1C4Z}.
FT   STRAND      679    684       {ECO:0000244|PDB:1C4Z}.
FT   TURN        687    689       {ECO:0000244|PDB:1C4Z}.
FT   STRAND      692    697       {ECO:0000244|PDB:1C4Z}.
FT   TURN        698    702       {ECO:0000244|PDB:1C4Z}.
FT   TURN        707    709       {ECO:0000244|PDB:1C4Z}.
FT   HELIX       710    722       {ECO:0000244|PDB:1C4Z}.
FT   HELIX       727    741       {ECO:0000244|PDB:1C4Z}.
FT   STRAND      742    744       {ECO:0000244|PDB:1C4Z}.
FT   HELIX       753    760       {ECO:0000244|PDB:1C4Z}.
FT   TURN        768    770       {ECO:0000244|PDB:1C4Z}.
FT   STRAND      775    779       {ECO:0000244|PDB:1C4Z}.
FT   HELIX       785    795       {ECO:0000244|PDB:1C4Z}.
FT   HELIX       799    809       {ECO:0000244|PDB:1C4Z}.
FT   STRAND      810    815       {ECO:0000244|PDB:1C4Z}.
FT   HELIX       820    823       {ECO:0000244|PDB:1C4Z}.
FT   STRAND      826    833       {ECO:0000244|PDB:1C4Z}.
FT   STRAND      839    841       {ECO:0000244|PDB:1C4Z}.
FT   HELIX       842    844       {ECO:0000244|PDB:1C4Z}.
FT   STRAND      846    851       {ECO:0000244|PDB:1C4Z}.
FT   HELIX       855    868       {ECO:0000244|PDB:1C4Z}.
SQ   SEQUENCE   875 AA;  100688 MW;  F80F0502B3B3838A CRC64;
     MEKLHQCYWK SGEPQSDDIE ASRMKRAAAK HLIERYYHQL TEGCGNEACT NEFCASCPTF
     LRMDNNAAAI KALELYKINA KLCDPHPSKK GASSAYLENS KGAPNNSCSE IKMNKKGARI
     DFKDVTYLTE EKVYEILELC REREDYSPLI RVIGRVFSSA EALVQSFRKV KQHTKEELKS
     LQAKDEDKDE DEKEKAACSA AAMEEDSEAS SSRIGDSSQG DNNLQKLGPD DVSVDIDAIR
     RVYTRLLSNE KIETAFLNAL VYLSPNVECD LTYHNVYSRD PNYLNLFIIV MENRNLHSPE
     YLEMALPLFC KAMSKLPLAA QGKLIRLWSK YNADQIRRMM ETFQQLITYK VISNEFNSRN
     LVNDDDAIVA ASKCLKMVYY ANVVGGEVDT NHNEEDDEEP IPESSELTLQ ELLGEERRNK
     KGPRVDPLET ELGVKTLDCR KPLIPFEEFI NEPLNEVLEM DKDYTFFKVE TENKFSFMTC
     PFILNAVTKN LGLYYDNRIR MYSERRITVL YSLVQGQQLN PYLRLKVRRD HIIDDALVRL
     EMIAMENPAD LKKQLYVEFE GEQGVDEGGV SKEFFQLVVE EIFNPDIGMF TYDESTKLFW
     FNPSSFETEG QFTLIGIVLG LAIYNNCILD VHFPMVVYRK LMGKKGTFRD LGDSHPVLYQ
     SLKDLLEYEG NVEDDMMITF QISQTDLFGN PMMYDLKENG DKIPITNENR KEFVNLYSDY
     ILNKSVEKQF KAFRRGFHMV TNESPLKYLF RPEEIELLIC GSRNLDFQAL EETTEYDGGY
     TRDSVLIREF WEIVHSFTDE QKRLFLQFTT GTDRAPVGGL GKLKMIIAKN GPDTERLPTS
     HTCFNVLLLP EYSSKEKLKE RLLKAITYAK GFGML
//
